Elicio Therapeutics, Inc.

NASDAQ:ELTX

Biotechnology

Healthcare
$2.70 -18.90%

-$0.89 today

Market cap
$51.48M
Beta
1.14
P/E (TTM)
-1.7
EPS (TTM)
-$2.21
52W Low $2.66High $16.00

Volume 0.41M

Average 0.34M

ELTX Other Non-Cash Items

Other non-cash adjustments that reconcile net income to operating cash flow.

Elicio Therapeutics, Inc.NASDAQ: ELTX

Other Non-Cash Items · Q1 FY2026 · quarter ended Mar 2026

Other non-cash items growth accelerates

Q1 FY2026 other non-cash items of $1.05M rose 62.1% year over year, ahead of the -62.3% change in trailing-twelve-month other non-cash items. Over 3 fiscal years it compounded at -21.0% a year.

Context

  • Other non-cash items increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +62.1% holds above the trailing-twelve-month pace of -62.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.05M+166.8% QoQ
Last fiscal yearDec 2025
$2.24M-72.8% YoY
LTMMar 2026
$2.64M-62.3% YoY
Other Non-Cash Items past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+62.1%——
1 year-72.8%——
3-year CAGR-21.0%——
5-year CAGR——
10-year CAGR——

Other Non-Cash Items history

USD · from the cash flow

Latest · FY2025
2.24M USD
Year-over-year change
-72.8%
4-year CAGR
+35.4%

Other Non-Cash Items vs competitors

How ELTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so other non-cash items is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -62.3% is the 8th highest of 9, against a peer median of +87.7%.
  • Over three fiscal years its annual growth of -21.0% compares with a peer median of +340.4%.
ELTX Competitors
Other Non-Cash Items for ELTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$8.26M USD+157.5%+340.4%463.2%
MOLNMolecular Partners AGLTM Mar 2026CHF 4.3M CHF+257.9%——
ELTXElicio Therapeutics, Inc.LTM Mar 2026$2.64M USD-62.3%-21.0%—
PEPGPepGen Inc.LTM Mar 2026$2.6M USD+225.7%——
ACTUActuate Therapeutics IncLTM Mar 2026$1.56M USD-13.9%——
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$1.19M USD+136.6%+854.5%37.5%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$1.13M USD-30.3%——
CRDFCardiff Oncology, Inc.LTM Mar 2026$804K USD+38.9%—153.1%
NKTXNkarta, Inc.LTM Mar 2026$561K USD-88.1%-9.8%—
Peer median (excluding ELTX) —+87.7%+340.4%153.1%

Competitors are the stored peer set for ELTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(26.4M)(28.21M)(35.2M)(51.9M)(39.57M)
Depreciation & Amortization251.45K1.06M1.17M1.18M1.13M
Deferred Income Tax52.96K0000
Stock-Based Compensation617.76K579K1.18M1.45M2.7M
Change in Working Capital872.44K(150K)(57K)3.96M(3.45M)
Accounts Receivables00000
Inventory00000
Accounts Payables30.23K1.13M23K(3.33M)(366K)
Other Working Capital842.21K(1.28M)(80K)7.29M(3.08M)
Other Non-Cash Items667.05K4.54M209K8.24M2.24M
Operating Cash Flow(23.94M)(22.18M)(32.69M)(37.07M)(36.95M)
Capital Expenditures(525.36K)(654K)(66K)(87K)(16K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0034K3K0
Investing Cash Flow(525.36K)(654K)(32K)(84K)(16K)
Debt Repayment14.03M010M19.73M9.87M
Common Stock Issued101.38K82K7M5.64M26.83M
Common Stock Repurchased00(150K)00
Dividends Paid00000
Other Financing Activities314.88K82K21.76M16.96M0
Financing Cash Flow19.39M21.2M38.61M42.32M36.7M
Effect of Forex Changes3K0(68K)22K40K
Net Change in Cash(5.07M)(1.63M)5.89M5.19M(233K)
Free Cash Flow(24.46M)(22.83M)(32.76M)(37.16M)(36.97M)

Elicio Therapeutics, Inc.

NASDAQ:ELTX

Intrinsic Alpha fair value

Locked

Current Price

$2.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.